AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.

More enterprises will prefer hybrid infrastructure solutions over time, and IBM is positioned to meet this need. IBM carries a sizable debt load, measuring $55 billion as of December 2024. However, ...

Net income of $13.7 million, or $0.71 per diluted share, for the three months ended December 31, 2024 compared to net loss of $7.9 million, or $0.41 per diluted share, for the three months ended Septe ...

Hearing plea of couple whose research work had been stolen, Bombay HC in 2023 ruled that ‘property’ under Section 15A of ...

Due to its significant market share and high gross margins in a structurally growing industry, ResMed has posted an average return on invested capital, or ROIC, of 20% over the last decade. We ...

Company strengthens full-year guidance following strong Q3 momentum TEMPE, Ariz. and PRAGUE, Jan. 30, 2025 /PRNewswire/ -- Gen Digital Inc. (NASDAQ: GEN), a global leader dedicated to Powering ...

AHCL IPO offers growth potential in the eye healthcare industry, but investors should wait for better cost structure clarity.

Market Services net revenue was $268 million in the fourth quarter of 2024, up 8% versus the prior year period, or 12% growth on an adjusted basis. The increase was primarily driven by a $15 million ...

Stacked with former execs from Ogilvy, Accenture Song, Disney Studios, and Goodby, Silverstein & Partners, The Intangibles is ...

The inaugural meeting, attended by representatives from various entities, outlined the scope of the registry, which tracks assets such as real estate, machinery, and intangible properties ...